Literature DB >> 31233933

The osteoclast, a target cell for microorganisms.

Brigitte Raynaud-Messina1, Christel Verollet1, Isabelle Maridonneau-Parini2.   

Abstract

Bone is a highly adaptive tissue with regenerative properties that is subject to numerous diseases. Infection is one of the causes of altered bone homeostasis. Bone infection happens subsequently to bone surgery or to systemic spreading of microorganisms. In addition to osteoblasts, osteoclasts (OCs) also constitute cell targets for pathogens. OCs are multinucleated cells that have the exclusive ability to resorb bone mineral tissue. However, the OC is much more than a bone eater. Beyond its role in the control of bone turnover, the OC is an immune cell that produces and senses inflammatory cytokines, ingests microorganisms and presents antigens. Today, increasing evidence shows that several pathogens use OC as a host cell to grow, generating debilitating bone defects. In this review, we exhaustively inventory the bacteria and viruses that infect OC and report the present knowledge in this topic. We point out that most of the microorganisms enhance the bone resorption activity of OC. We notice that pathogen interactions with the OC require further investigation, in particular to validate the OC as a host cell in vivo and to identify the cellular mechanisms involved in altered bone resorption. Thus, we conclude that the OC is a new cell target for pathogens; this new research area paves the way for new therapeutic strategies in the infections causing bone defects.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bacteria; Bone defects; Innate immunity; Osteoclasts; Viruses

Year:  2019        PMID: 31233933     DOI: 10.1016/j.bone.2019.06.023

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

1.  Zika virus infects human osteoclasts and blocks differentiation and bone resorption.

Authors:  Noreen Mumtaz; Marijke Koedam; Johannes P T M van Leeuwen; Marion P G Koopmans; Bram C J van der Eerden; Barry Rockx
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

2.  Periprosthetic Joint Infection Caused by Gram-Positive Versus Gram-Negative Bacteria: Lipopolysaccharide, but not Lipoteichoic Acid, Exerts Adverse Osteoclast-Mediated Effects on the Bone.

Authors:  Mei-Feng Chen; Chih-Hsiang Chang; Chih-Chien Hu; Ying-Yu Wu; Yuhan Chang; Steve W N Ueng
Journal:  J Clin Med       Date:  2019-08-23       Impact factor: 4.241

3.  Gamabufotalin Inhibits Osteoclastgenesis and Counteracts Estrogen-Deficient Bone Loss in Mice by Suppressing RANKL-Induced NF-κB and ERK/MAPK Pathways.

Authors:  Kaiqiang Sun; Jian Zhu; Yi Deng; Ximing Xu; Fanqi Kong; Xiaofei Sun; Le Huan; Changzhen Ren; Jingchuan Sun; Jiangang Shi
Journal:  Front Pharmacol       Date:  2021-04-23       Impact factor: 5.810

4.  α-Mangostin inhibits LPS-induced bone resorption by restricting osteoclastogenesis via NF-κB and MAPK signaling.

Authors:  Wenkan Zhang; Guangyao Jiang; Xiaozhong Zhou; Leyi Huang; Jiahong Meng; Bin He; Yiying Qi
Journal:  Chin Med       Date:  2022-03-05       Impact factor: 5.455

5.  PERK controls bone homeostasis through the regulation of osteoclast differentiation and function.

Authors:  Jiachao Guo; Ranyue Ren; Kai Sun; Xudong Yao; Jiamin Lin; Genchun Wang; Zhou Guo; Tao Xu; Fengjing Guo
Journal:  Cell Death Dis       Date:  2020-10-13       Impact factor: 8.469

6.  Salubrinal Alleviates Collagen-Induced Arthritis through Promoting P65 Degradation in Osteoclastogenesis.

Authors:  Ziyu Wang; Zijian Li; Guojue Wang; Ying Sun; Yuanyang Yuan; Hong Nie
Journal:  Int J Mol Sci       Date:  2021-03-28       Impact factor: 5.923

Review 7.  Cellular and molecular actors of myeloid cell fusion: podosomes and tunneling nanotubes call the tune.

Authors:  Ophélie Dufrançais; Rémi Mascarau; Brigitte Raynaud-Messina; Christel Vérollet; Renaud Poincloux; Isabelle Maridonneau-Parini
Journal:  Cell Mol Life Sci       Date:  2021-07-23       Impact factor: 9.261

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.